PTC aims again for FDA review of Duchenne drug despite latest miss

PTC Therapeutics appears to have hit another hurdle in its quest to prove its Duchenne muscular dystrophy drug Translarna, reporting Thursday the treatment didn't significantly increase the amount of a key muscle building protein in a group of 18 boys.